Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
148.4
USD
|
-1.07%
|
|
+0.45%
|
-22.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,840
|
15,100
|
20,282
|
29,238
|
24,021
|
18,775
|
-
|
-
|
Enterprise Value (EV)
1 |
12,293
|
13,417
|
18,522
|
28,132
|
23,979
|
17,648
|
18,332
|
17,599
|
P/E ratio
|
-14.2
x
|
-17.4
x
|
-23.6
x
|
-25.6
x
|
-54.4
x
|
-42
x
|
-79.7
x
|
80.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
58.4
x
|
30.6
x
|
24
x
|
28.2
x
|
13.1
x
|
10
x
|
8.31
x
|
6.25
x
|
EV / Revenue
|
55.9
x
|
27.2
x
|
21.9
x
|
27.1
x
|
13.1
x
|
9.43
x
|
8.11
x
|
5.86
x
|
EV / EBITDA
|
-13.9
x
|
-16.9
x
|
-28
x
|
-38
x
|
-
|
-55.2
x
|
3,790
x
|
22.8
x
|
EV / FCF
|
-29.4
x
|
-19.6
x
|
-25.8
x
|
-45.9
x
|
572
x
|
-55.6
x
|
-2,015
x
|
25.6
x
|
FCF Yield
|
-3.41%
|
-5.11%
|
-3.88%
|
-2.18%
|
0.17%
|
-1.8%
|
-0.05%
|
3.9%
|
Price to Book
|
8.98
x
|
14.9
x
|
34.6
x
|
-186
x
|
-109
x
|
-119
x
|
-71.2
x
|
233
x
|
Nbr of stocks (in thousands)
|
111,490
|
116,181
|
119,601
|
123,028
|
125,493
|
126,492
|
-
|
-
|
Reference price
2 |
115.2
|
130.0
|
169.6
|
237.6
|
191.4
|
148.4
|
148.4
|
148.4
|
Announcement Date
|
2/6/20
|
2/11/21
|
2/10/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
219.8
|
492.9
|
844.3
|
1,037
|
1,828
|
1,872
|
2,259
|
3,005
|
EBITDA
1 |
-885.1
|
-793.7
|
-661.1
|
-740.6
|
-
|
-319.5
|
4.836
|
770.6
|
EBIT
1 |
-939.4
|
-828.4
|
-708.7
|
-785.1
|
-282.2
|
-371.6
|
-194.4
|
302.3
|
Operating Margin
|
-427.5%
|
-168.09%
|
-83.93%
|
-75.68%
|
-15.43%
|
-19.85%
|
-8.61%
|
10.06%
|
Earnings before Tax (EBT)
1 |
-885.3
|
-855.6
|
-852.1
|
-1,127
|
-433.5
|
-475.5
|
-285.5
|
212.3
|
Net income
1 |
-886.1
|
-858.3
|
-852.8
|
-1,131
|
-440.2
|
-450.8
|
-256.9
|
240.3
|
Net margin
|
-403.24%
|
-174.15%
|
-101.01%
|
-109.04%
|
-24.08%
|
-24.08%
|
-11.37%
|
8%
|
EPS
2 |
-8.110
|
-7.460
|
-7.200
|
-9.300
|
-3.520
|
-3.535
|
-1.862
|
1.845
|
Free Cash Flow
1 |
-418.6
|
-685.3
|
-718.1
|
-613.3
|
41.94
|
-317.6
|
-9.1
|
686.9
|
FCF margin
|
-190.48%
|
-139.05%
|
-85.05%
|
-59.12%
|
2.29%
|
-16.97%
|
-0.4%
|
22.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
89.14%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
285.85%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
2/11/21
|
2/10/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
258.5
|
213.3
|
224.8
|
264.3
|
335
|
319.3
|
318.8
|
750.5
|
439.7
|
494.3
|
444.8
|
459.2
|
471.1
|
489.6
|
512.7
|
EBITDA
1 |
-183.2
|
-137.3
|
-181.6
|
-247.4
|
-174.3
|
-135.7
|
-216.7
|
227.2
|
-
|
-29.92
|
-114.5
|
-79.7
|
-56.9
|
-
|
-
|
EBIT
1 |
-194.6
|
-146.7
|
-191.7
|
-258
|
-188.6
|
-149.8
|
-229.8
|
213.9
|
-116.4
|
-43.44
|
-118.2
|
-113
|
-110.1
|
-129.4
|
-135.9
|
Operating Margin
|
-75.26%
|
-68.8%
|
-85.26%
|
-97.63%
|
-56.3%
|
-46.92%
|
-72.1%
|
28.5%
|
-26.47%
|
-8.79%
|
-26.58%
|
-24.61%
|
-23.37%
|
-26.42%
|
-26.51%
|
Earnings before Tax (EBT)
1 |
-260.3
|
-239.4
|
-274.7
|
-405.9
|
-207
|
-172.4
|
-274.2
|
150.7
|
-137.7
|
-63.59
|
-138
|
-138.6
|
-137.3
|
-150.5
|
-162.7
|
Net income
1 |
-258.5
|
-240.3
|
-277.4
|
-405.9
|
-207.5
|
-174.1
|
-276
|
147.8
|
-137.9
|
-65.94
|
-139.5
|
-136.9
|
-124.5
|
-152.3
|
-164.6
|
Net margin
|
-99.97%
|
-112.7%
|
-123.39%
|
-153.58%
|
-61.93%
|
-54.53%
|
-86.59%
|
19.69%
|
-31.35%
|
-13.34%
|
-31.36%
|
-29.8%
|
-26.44%
|
-31.11%
|
-32.11%
|
EPS
2 |
-2.160
|
-2.000
|
-2.290
|
-3.320
|
-1.680
|
-1.400
|
-2.210
|
1.180
|
-1.100
|
-0.5200
|
-1.113
|
-1.063
|
-0.9718
|
-1.052
|
-1.020
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
4/28/22
|
7/28/22
|
10/27/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
547
|
1,683
|
1,760
|
1,105
|
41.4
|
1,127
|
443
|
1,176
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-419
|
-685
|
-718
|
-613
|
41.9
|
-318
|
-9.1
|
687
|
ROE (net income / shareholders' equity)
|
-53.4%
|
-69.9%
|
-106%
|
-526%
|
-
|
-551%
|
-65.2%
|
78.7%
|
ROA (Net income/ Total Assets)
|
-44.6%
|
-29.6%
|
-24.2%
|
-31.5%
|
-11.9%
|
-5.5%
|
-5.12%
|
-0.12%
|
Assets
1 |
1,985
|
2,901
|
3,525
|
3,595
|
3,688
|
8,197
|
5,018
|
-204,509
|
Book Value Per Share
2 |
12.80
|
8.730
|
4.890
|
-1.280
|
-1.750
|
-1.250
|
-2.090
|
0.6400
|
Cash Flow per Share
2 |
-
|
-5.350
|
-5.420
|
-4.450
|
0.8300
|
-0.9500
|
2.830
|
5.910
|
Capex
1 |
140
|
70.4
|
76.4
|
72.1
|
62.2
|
66.2
|
86.8
|
120
|
Capex / Sales
|
63.78%
|
14.28%
|
9.05%
|
6.95%
|
3.4%
|
3.54%
|
3.84%
|
4%
|
Announcement Date
|
2/6/20
|
2/11/21
|
2/10/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
148.4
USD Average target price
220.4
USD Spread / Average Target +48.48% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.45% | 18.78B | | +43.36% | 54.64B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | +0.04% | 12.16B | | +25.12% | 12.21B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|